Brief: Hansa Biopharma And German Payer Head Association Agree On Reimbursement Price For Idefirix
15/03/2022 14:28
March 15 (Reuters) - Hansa Biopharma AB HNSA.ST :
* HANSA BIOPHARMA AND GERMAN PAYER HEAD ASSOCIATION AGREE ON
REIMBURSEMENT PRICE FOR IDEFIRIX ® (IMLIFIDASE) AS
DESENSITIZATION TREATMENT FOR HIGHLY SENSITIZED KIDNEY
TRANSPLANT PATIENTS
* AGREEMENT FOR REIMBURSEMENT COVERS ENTIRE STATUTORY HEALTH
INSURANCE SYSTEM AND IS ALSO ADOPTED BY PRIVATE HEALTH
INSURANCES IN GERMANY.
Source text for Eikon: ID:nWkr5pW8Cv
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS